Gilead (Myogen / GSK)

Ambrisentan® is a non-sulfonamide, propanoic acid-class, endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. Activation of the ETA receptor by endothelin, a small peptide hormone, leads to vasoconstriction and cell proliferation. PAH is associated with elevated endothelin blood levels. Ambrisentan has been granted orphan drug designation for the treatment of PAH in both the United States and European Union. Currently in Phase III trials.

Gilead (Myogen / GSK)

Flolan® For primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA class III and class IV patients who do not respond adequately to conventional therapy.